319 related articles for article (PubMed ID: 27466355)
1. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
Wang B; Li S; Meng X; Shang H; Guan Y
Tumour Biol; 2015 Aug; 36(8):6433-43. PubMed ID: 25801244
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
Patel NR; Rathi A; Mongayt D; Torchilin VP
Int J Pharm; 2011 Sep; 416(1):296-9. PubMed ID: 21703341
[TBL] [Abstract][Full Text] [Related]
5. Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors.
Syed SB; Lin SY; Arya H; Fu IH; Yeh TK; Charles MRC; Periyasamy L; Hsieh HP; Coumar MS
Chem Biol Drug Des; 2021 Jan; 97(1):51-66. PubMed ID: 32633857
[TBL] [Abstract][Full Text] [Related]
6. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
9. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
10. Reversal of P-glycoprotein-mediated multidrug resistance by novel curcumin analogues in paclitaxel-resistant human breast cancer cells.
Gao L; Zhao P; Li Y; Yang D; Hu P; Li L; Cheng Y; Yao H
Biochem Cell Biol; 2020 Aug; 98(4):484-491. PubMed ID: 31967866
[TBL] [Abstract][Full Text] [Related]
11. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
12. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
13. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
15. 10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein.
Lee DH; Hasanuzzaman M; Kwon D; Choi HY; Kim SM; Kim DJ; Kang DJ; Hwang TH; Kim HH; Shin HJ; Shin JG; Oh S; Lee S; Kim SW
Curr Pharm Des; 2018; 24(46):5590-5597. PubMed ID: 30799787
[TBL] [Abstract][Full Text] [Related]
16. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
17. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
19. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
20. Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells.
Ding Q; Niu P; Zhu Y; Chen H; Shi D
J Nat Med; 2022 Jan; 76(1):220-233. PubMed ID: 34751899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]